A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study

BACKGROUND: Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR). We studied its efficacy and tolerability in persistent or recurrent cervical cancer patients. METHODS: Eligible patients had at least one prior c...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Gynecol Oncol
Egile Nagusiak: Chan, John K., Deng, Wei, Higgins, Robert V., Tewari, Krishnansu S., Bonebrake, Albert J., Hicks, Michael, Gaillard, Stephanie, Ramirez, Pedro T., Chafe, Weldon, Monk, Bradley J., Aghajanian, Carol
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728988/
https://ncbi.nlm.nih.gov/pubmed/28728751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.05.033
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak